Skip to main content
Premium Trial:

Request an Annual Quote

J&J Pharma R&D Taps Entelos for In Silico Studies of Type-2 Diabetes Therapies

NEW YORK (GenomeWeb News) - Entelos said today that has signed an agreement with Johnson & Johnson Pharmaceutical Research & Development to use its predictive computer models of human physiology to study new therapies for type-2 diabetes.
 
Under the agreement, Entelos will use its in silico “virtual patients” to discover and evaluate therapies for the disease.
 
The companies signed a collaborative agreement in March 2006 covering multiple therapeutic areas, but did not provide further details at the time.
 
Financial terms of the agreement were not released.
 
Entelos' CEO, James Karis, said the agreement is part of the company's strategy to offer its predictive services "in chronic disease areas where multiple drugs, treatment choices, and large differences between patients make it difficult for health-care providers to select the best treatments."
 

Entelos has ongoing internal drug programs for rheumatoid arthritis and women's health. It is also developing an oncology model and is collaborating with the US Food and Drug Administration to develop a model of drug-induced liver injury.

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.